Vertex Pharmaceuticals Incorporated held its annual meeting of shareholders on May 15, 2024. During the meeting, shareholders voted on several key proposals. The election of the Board of Directors was a primary focus, with Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry, and Suketu Upadhyay all being elected to serve until the 2025 annual meeting. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The 2023 compensation program for the company's named executive officers was approved on an advisory basis. A shareholder proposal regarding a special shareholder meeting improvement was also approved. However, a proposal concerning a report on racial and gender pay gaps was not approved. The results of the votes were documented and the report was signed by Jonathan Biller, Executive Vice President and Chief Legal Officer of Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated held its annual meeting of shareholders on May 15, 2024. During the meeting, shareholders voted on several key proposals. The election of the Board of Directors was a primary focus, with Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry, and Suketu Upadhyay all being elected to serve until the 2025 annual meeting. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The 2023 compensation program for the company's named executive officers was approved on an advisory basis. A shareholder proposal regarding a special shareholder meeting improvement was also approved. However, a proposal concerning a report on racial and gender pay gaps was not approved. The results of the votes were documented and the report was signed by Jonathan Biller, Executive Vice President and Chief Legal Officer of Vertex Pharmaceuticals.